http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0434707-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
| filingDate | 1989-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29042e398c3edaaac18f0274fc190d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a079d6172a1fb1d237e73b48c4d11e63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_186c9a341caf35ed6c11c719edfc5b7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d3c0319b90260f1bbb919d8fa722c13 |
| publicationDate | 1991-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0434707-A1 |
| titleOfInvention | 6-oxo-9-fluor-prostaglandin derivatives, process for producing them and their use as drugs |
| abstract | Derivatives of 6-oxo-9-fluor-prostaglandin have the formula (1), in which R1 represents the residues COOR2 or CONHSO2R2, where R2 is a C5-C6-cycloalkyl or C6-C12-aryl group or a pentagonal heterocyclic residue or hexagonal, or when R1 is COOR2, R2 can represent a hydrogen atom or a phenacyl free or substituted by 1-3 halogen atoms, A is a CH = CH or -C = C- group with E configuration, W is a free or functionally transformed hydroxymethylene group or a free or functionally transformed group (a), while the OH group can be located in alpha or beta, D is a straight or branched chain alkylene group having between 1 and 5 atoms or is a direct bond, E is a -C = C- group, a C2-C4-alkenyl group, or a group (b); R3 is a hydrogen atom, a C2-C4-alkenylene group, a C3-C10-cycloalkyl group, an optionally substituted C6-C12-aryl group or a pentagonal or hexagonal heterocyclic group, R4 is a hydrogen atom, a methyl group or a free or functionally transformed hydroxyl group, and when R2 represents a hydrogen atom, its salts with physiologically compatible bases, cyclodextrin alpha, beta or gamma clathrates. The invention also relates to the compounds of formula (I) encapsulated in liposomes, their production process and their pharmaceutical use. |
| priorityDate | 1988-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 91.